Peripheral neuropathy Board decisions

The Board denied service connection for an upper stomach condition and peripheral neuropathy of all extremities, finding that the conditions were not directly related to the Veteran's presumed exposure to Agent Orange in Vietnam.

The appeal was dismissed due to the Veteran's death during the pendency of the appeal.

The Board granted an increased 40 percent rating for small fiber peripheral neuropathy of the right and left lower extremities.

The Board granted earlier effective dates for the grant of service connection for diabetes mellitus II with erectile dysfunction and certain diabetic peripheral neuropathies, but denied them for others.

The Board denied the claims for service connection for diabetes mellitus type II, bladder cancer, left and right leg peripheral neuropathy as there was no evidence of in-service incurrence or aggravation of a disease or injury, and no causal relationship between the current disabilities and the Veteran's military service.

The Board remands the matter for further development, including obtaining additional evidence and a new VA examination to determine if the Veteran's BLE disabilities are related to in-service environmental exposures.

The Board granted earlier effective dates of January 21, 2003, for the award of service connection for diabetic peripheral neuropathy in both upper extremities and denied higher disability ratings.

The Board remands the claims for service connection for bilateral upper and lower extremity peripheral neuropathy as additional development is necessary.

The Board granted service connection for bilateral upper and lower extremity peripheral neuropathy, finding a nexus to the Veteran's in-service herbicide agent exposure.

The Board remands the claims for service connection for migraine headaches and peripheral neuropathy, to include as due to Persian Gulf War service and/or service-connected disabilities, for further development of evidence.

The Board granted earlier effective dates of September 16, 1983 for the lumbar spine disability and related conditions, but denied increased ratings for peripheral neuropathy in both lower extremities and a rating for radiculopathy.

The Board remands the claims for service connection for right lower extremity peripheral neuropathy, right upper extremity peripheral neuropathy, and left lower extremity peripheral neuropathy due to a pre-decisional duty to assist error in failing to obtain an adequate medical opinion.

The Board denied service connection for various conditions, including bilateral knee, hearing loss, tinnitus, skin rash, and sleep apnea. The Veteran was granted a 20 percent rating for diabetic neuropathy of the femoral nerve in both lower extremities.

The Board remands the issues for further development, including obtaining a new TERA memorandum and appropriate VA opinions to determine if the Veteran's claimed conditions are related to his service exposure.

The Board denied an earlier effective date for the grant of service connection for peripheral neuropathy of both upper extremities and remanded increased rating claims for peripheral neuropathy of all four extremities as well as a higher rating claim for prostate cancer with erectile dysfunction.

The Board granted earlier effective dates of August 10, 2022, for the grants of service connection for right and left lower extremity diabetic peripheral neuropathy and diabetic retinopathy. The claim for an increased rating for diabetes mellitus, type II, with erectile dysfunction was denied.

The Board remands the veteran's claims for increased ratings and other benefits due to incomplete records.

The Board remands the claims for service connection for various disabilities due to a lack of proper notification and scheduling of VA examinations.

The Board denied earlier effective dates for service connection and remanded a compensable rating claim due to missing pulmonary function test results.

The Board denied service connection for headaches, an acquired psychiatric disorder (generalized anxiety with insomnia features), and diabetic peripheral neuropathy of the upper and lower extremities. The effective date for these conditions was set to October 2, 2023.